OncoMatch/Clinical Trials/NCT06806033
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Is NCT06806033 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Obinutuzumab and Glofitamab for b-cell non-hodgkins lymphoma.
Treatment: Obinutuzumab · Glofitamab · Gemcitabine · Oxaliplatin — This Phase II trial evaluates the optimization of the cytokine release syndrome (CRS) profile for glofitamab in combination with gemcitabine and oxaliplatin (Glofit-GemOx) in participants with relapsed or refractory aggressive B-cell Non-Hodgkin's lymphoma. The study utilizes an optimized steroid premedication regimen and monitoring schedule specifically designed to enable the administration of the treatment regimen in an outpatient setting.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MYC rearrangement
DLBCL/HGBL with MYC and BCL2 rearrangements
Required: BCL2 rearrangement
DLBCL/HGBL with MYC and BCL2 rearrangements
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic therapy
At least one line of prior systemic therapy
Cannot have received: glofitamab or other bispecific antibodies targeting both CD20 and CD3
Prior treatment with glofitamab or other bispecific antibodies targeting both CD20 and CD3
Cannot have received: gemcitabine (gemcitabine)
Prior treatment with gemcitabine or oxaliplatin
Cannot have received: oxaliplatin (oxaliplatin)
Prior treatment with gemcitabine or oxaliplatin
Cannot have received: monoclonal antibodies
Treatment with monoclonal antibodies for the purposes of treating cancer within 4 weeks prior to first study treatment
Cannot have received: radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent
Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 2 weeks prior to first study treatment
Lab requirements
Blood counts
adequate hematologic function
Kidney function
adequate renal function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Alaska Oncology & Hematology, LLC · Anchorage, Alaska
- Community Cancer Institute (CCI) · Clovis, California
- Providence Medical Foundation · Fullerton, California
- Los Angeles Cancer Network · Glendale, California
- Valkyrie Clinical Trials · Los Angeles, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06806033 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior glofitamab or other bispecific antibodies targeting both CD20 and CD3, gemcitabine, oxaliplatin disqualifies patients from enrollment.
Does this trial require MYC?
Yes, MYC rearrangement is a required biomarker for enrollment.
Does this trial require BCL2?
Yes, BCL2 rearrangement is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages